Motor Neurone Disease

  • Nages Nagaratnam
  • Kujan Nagaratnam
  • Gary Cheuk
Reference work entry

Abstract

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder. It affects both upper and lower motor neurons and is characterised by a progressive degeneration and death of the anterior horn cells, cortico-spinal tracts and/or bulbar motor nuclei. The cause is unknown. There is an association between frontotemporal dementia (FTD) and ALS. ALS commonly occurs between the ages of 40 and 60 years, and males are affected more than females. The disease is relentlessly progressive. The median life span is about 4 years. Most with ALS will die from respiratory failure. Symptoms of bulbar involvement usually imply a rapid course usually with survival of a year. There is no cure, and medical care is mainly palliation and involves a multidisciplinary approach.

Keywords

Motor neurone disease Amyotrophic lateral sclerosis Frontotemporal dementia (FTD) Riluzole El Escorial criteria Awaji criteria 

References

  1. 1.
    McDermott CJ, Shaw PJ. Diagnosis and management of motor neurone disease. BMJ. 2008; 336:658–62.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Cronin S, Hardiman O, Tragnor BJ. Ethnic variation in the incidence of amyotrophic lateral sclerosis. :A systematic review. Neurology. 2007;68:1002–1007.CrossRefPubMedGoogle Scholar
  3. 3.
    Alonso A, Logroscino G, Jick SS, Herman MA. Incidence and life time risk of motor neurone disease in the United Kingdom: a population based study. Eur J Neurol. 2009; 16(6);745–751.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Forbes RB, Colville S, Parra HJ, Sudingier LJ. The incidence of motor neurone disease in Scotland. J Neurol. 2007;254(7):866–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Chio A, Mora G,Calvo A, Mazzini L, Bottachi E, Mutni R. Epidemiology of amyotrophic lateral sclerosis in Italy: a ten year population based study.Neurology. 2009;72(8):725–31.CrossRefPubMedGoogle Scholar
  6. 6.
    Rocha JA, Reis S, Simeos F, Fonseca J, Mendes Ribeiro J. Diagnostic investigation and multidisciplinary management in motor neurone disease. J Neurol. 2005;252(12): 1435–17.CrossRefPubMedGoogle Scholar
  7. 7.
    Wilburn AJ. The ‘split hand’ syndrome. Muscle Nerve. 2000;23:138.CrossRefGoogle Scholar
  8. 8.
    Kuwabara S, Sonoo M, Komori T, Shimizu T, Hirashima F, Inaba A, et al. Dissociated small hand muscle atrophy in amyotrophic lateral sclerosis: frequency, extent and specificity. Muscle Nerve. 2008;37:426–30.CrossRefPubMedGoogle Scholar
  9. 9.
    Caga J, Rasey E, Hogden A, Mioshi E, Kiernan MC. A longer diagnostic interval is a risk for depression in amyotrophic lateral sclerosis. Paliat Support Care. 2014;13:1019–24.CrossRefGoogle Scholar
  10. 10.
    Lomen-Hoerth C, Murphy J, Longmore S, Kramer JH, Olney RK, Miller B. Are amyotrophic lateral sclerosis patients cognitively normal? Neurology. 2003;60:1094–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Xue LY. The useof EMG/NCS in neuromuscular disorders. New Engl Neurological Assoc.PC 2013. www.nenero.com/theuseof_-emgries_in_neuromuscular_disorders accessed 10 May 2016.
  12. 12.
    Belsh JM. Diagnosticchallenges in ALS. Neurology. 1999;53(8Suppl 5):S26–30.PubMedGoogle Scholar
  13. 13.
    Armon C. Amyotrophic lateral sclerosis workshop.Medscape. emedicine.medscape.com/article/1170097-workshop. accessed 10 May 2016.
  14. 14.
    Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. ALS other Motor Neuron Disord. 2000:1:293–299.Google Scholar
  15. 15.
    Dengler R. Diagnostic criteria of amyotrophic lateral sclerosis.(ALS). Romanian J Neurol. 2010;9(4):165–8.Google Scholar
  16. 16.
    de Carvalho M, Dengler R, Eisen A, England JD, Kai R, Kimura J, et al. Electrodiagnostic criteria for diagnosis of amyotrophic lateral sclerosis. Clin Neurophysiol 2008;119:497–503.CrossRefPubMedGoogle Scholar
  17. 17.
    Leigh N, Lloyd CM, Ray-Chaudhuri K, Motor Neurone Disease. In: Wiles CM ed Management of neurological diseases London. BMJ publishing Group 195;241:71.Google Scholar
  18. 18.
    Van den Berg JP, Kalmijn S, Lindeman E, Veldink JH, de Visser M, Van der Graaff MM, et al. Multidisciplinary ALS care improves quality of life in patients with ALS. Neurology. 2005;65:1264–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Traynor BJ, Alexander M, Corr B, Frost E, Hardimasn O. Effect of a multidisciplinary amyotrophic lateral sclerosis(ALS)clinic on ALS survival: a population based study. 1996–2000. J Neurol Neursurg Psychiatry. 2003;74:1258–61.CrossRefGoogle Scholar
  20. 20.
    Karussis D, Karageorgion C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori JM, Kassis I, et al. Transplantation of mesenchymal stem cell transplantation in patients with multiple sclerosis in amyotrophic lateral sclerosis. Arch Neurol. 2010;67(10):1187–1194.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Chancellor AM, Slattery JM, Fraser H, Swingler RJ, Holloway SM,Warlow CP. The prognosis of adult onset motor neurone disease: A prospective study based in the Scottish Motor Neurone Disease Register. J Neurol 1993;240:330–46.CrossRefGoogle Scholar
  22. 22.
    Bourke SC, Shaw PJ, Gibson J. Respiratory function vs sleep disordered breathing as predictors of quality of life in amyotrophic lateral sclerosis. Neurology. 2001;52:2040–44.CrossRefGoogle Scholar
  23. 23.
    Desport JC, Preux PM, Truong TC,Vallat JM, Sautereau D, Couratier P. Nutritional status is a prognostic factor for survival of amyotrophic lateral sclerosis patients. Neurology. 1999;53:1059–63.CrossRefPubMedGoogle Scholar
  24. 24.
    Van Der Steen I, Van Den Berg Jan-P, Buskeus E, Lindeman E, Van Den Berg LH. The costs of amyotrophic lateral sclerosis, according to type of care. J ALS 2009;10(1): http://www.tandfonline.com/doi/abs/10.1080/1748296082103131?journalCode+iafd19 accessed on 9 November 2015.
  25. 25.
    Korner S, Hendricks M, Kollewe K, Zapf A, Dengler R, Silani V, et al. Weight loss dysphagia and supplement intake in patients with amyotrophic lateral sclerosis (ALS) impact on quality of life and therapeutic options. BMC Neurology. 2013;13:84.  https://doi.org/10.1186/1471-23-77-13-84.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Nages Nagaratnam
    • 1
  • Kujan Nagaratnam
    • 1
  • Gary Cheuk
    • 2
  1. 1.The University of SydneyWestmead Clinical SchoolWestmeadAustralia
  2. 2.Rehabilitation and Aged Care ServiceBlacktown-Mt Druitt HospitalMount DruittAustralia

Personalised recommendations